U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H29N3O2
Molecular Weight 379.4953
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXYPERTINE

SMILES

COC1=CC2=C(C=C1OC)C(CCN3CCN(CC3)C4=CC=CC=C4)=C(C)N2

InChI

InChIKey=XCWPUUGSGHNIDZ-UHFFFAOYSA-N
InChI=1S/C23H29N3O2/c1-17-19(20-15-22(27-2)23(28-3)16-21(20)24-17)9-10-25-11-13-26(14-12-25)18-7-5-4-6-8-18/h4-8,15-16,24H,9-14H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C23H29N3O2
Molecular Weight 379.4953
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://imr.sagepub.com/content/1/6/573.full.pdf

Oxypertine (Equipertine, Forit, Integrin, Lanturil, Lotawin, Opertil) is a neuroleptic drug and was originally introduced as a treatment for schizophrenia in the 1960s. Oxypertine is an indole derivative with general properties similar to those of the phenothiazine, chlorpromazine. It has been given by mouth in the treatment of various psychoses including schizophrenia, mania, and disturbed behaviour, and of severe anxiety. Like reserpine and tetrabenazine, oxypertine depletes catecholamines, though not serotonin, possibly underlying its neuroleptic efficacy. The molecular structure is strongly similar to solypertine and milipertine.

CNS Activity

CNS Active
3913
Curator's Comment: Oxypertine penetrates the blood-brain barrier in mice and cats

Originator

Archer, S. et al.
2
Curator's Comment: Oxypertine was first synthesized by Archer et al

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 54.0 nM [IC50]
Antagonist
2778
 210.0 nM [IC50]
Inhibitor
8297
Antagonist
2778
 25.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Approved
8429
FORIT

Approved Use

Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.
Primary
Approved
8429
FORIT

Approved Use

Oxypertine is primarily indicated in conditions like Mania, Psychosis, Schizophrenia.
PubMed

PubMed

TitleDatePubMed
Biochemical versus psychopathological action profile of neuroleptics: a comparative study of chlorpromazine and oxypertine in acute psychotic disorders.
1975 May-Jun
Effects of sulpiride and oxypertine on the dopaminergic system in the rat striatum.
1992
Enhanced separation of filamentous fungi by ultrasonic field: possible usage in repeated batch processes.
2002 Aug 7
Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.
2003 Dec 25
GAF film dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train.
2003 Jun
The "Haptic Finger"- a new device for monitoring skin condition.
2003 May
Towards pick-and-place assembly of nanostructures.
2004 Mar
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain.
2004 Nov 26
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.
2010 Mar 3
Patents

Patents

20010012620
4
20010029019
2
JP2001309790A
2
JP2001508690A
2
JP2002543060A
2
JP2002544521A
5
JP2003246749A
2
JP2006523456A
2
JP2006524634A
46
JP2007505158A
9
JP2007513081A
2
JP2007514770A
75
JP2007518711A
6
JP2007521009A
2
JP2007528703A
2
JP2007528706A
2
JP2008528532A
12
JP2008533263A
2
JP2009100763A
2
JP2009509661A
3
JP2009513722A
2
JP2010029203A
2
JP2011032286A
2
JP2011116791A
2
JP2011526186A
2
JP2013253987A
2
JP4652570B2
2
JP4656937B2
2
JP4667873B2
2
JP4787447B2
2
JP5378303B2
2
JPH08211055A
2

Sample Use Guides

In Vivo Use Guide
Oxypertine 20 mg given orally as a nocturnal sedative and again on the morning of operation produced relief of anxiety
Route of Administration: Oral
In Vitro Use Guide
Oxypertine inhibited [3H]WB-4101 binding in rat cerebral cortex membranes with IC50 54 nM
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:55:05 GMT 2023
Edited
by admin
on Sat Dec 16 16:55:05 GMT 2023
Record UNII
5JGL4G25R7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXYPERTINE
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
5,6-Dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]indole
Systematic Name English
WIN 18,501-2
Code English
WIN-18501-2
Code English
OXYPERTINE [MART.]
Common Name English
OXYPERTINE [USAN]
Common Name English
OXYPERTINE [JAN]
Common Name English
1H-INDOLE, 5,6-DIMETHOXY-2-METHYL-3-(2-(4-PHENYL-1-PIPERAZINYL)ETHYL)-
Systematic Name English
OXYPERTINE [MI]
Common Name English
WIN-185012
Code English
oxypertine [INN]
Common Name English
FORIT
Brand Name English
Oxypertine [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QN05AE01
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
NCI_THESAURUS C66883
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
WHO-ATC N05AE01
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
Code System Code Type Description
EVMPD
SUB09571MIG
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
NCI_THESAURUS
C87711
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
MESH
C084589
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
FDA UNII
5JGL4G25R7
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
INN
1293
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-818-3
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
WIKIPEDIA
OXYPERTINE
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
DRUG CENTRAL
2035
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
EPA CompTox
DTXSID20165185
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
CAS
153-87-7
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
DRUG BANK
DB13403
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
SMS_ID
100000083287
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
MERCK INDEX
m8340
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY Merck Index
PUBCHEM
4640
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107011
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY
RXCUI
7815
Created by admin on Sat Dec 16 16:55:05 GMT 2023 , Edited by admin on Sat Dec 16 16:55:05 GMT 2023
PRIMARY RxNorm
Related Record Type Details
Structure of OXYPERTINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966